Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Inks $140 Million Cancer Deal with AstraZeneca

publication date: Dec 21, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma announced a new partnership with AstraZeneca that will jointly develop a pre-clinical cancer molecule, volitinib (HMPL-504). Volitinib is a novel inhibitor of the c-Met receptor tyrosine kinase. According to HMP, the drug candidate will soon begin a Phase I trial. AstraZeneca made a $20 million upfront payment, and the agreement calls for up to $120 million in milestones. More details....

Stock Symbol: (NYSE: AZN)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors